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Objective: This study examines the cardiac and peripheral gene expression re-
sponses to cardiopulmonary bypass and cardioplegic arrest.
Methods: Atrial myocardium and skeletal muscle were harvested from 16 patients
who underwent coronary artery bypass grafting before and after cardiopulmonary
bypass and cardioplegic arrest. Ten sample pairs were selected for patient
similarity, and oligonucleotide microarray analyses of 12,625 genes were per-
formed using matched precardiopulmonary bypass tissues as controls. Array
results were validated with Northern blotting, real-time polymerase chain reac-
tion, in situ hybridization, and immunoblotting. Statistical analyses were non-
parametric.
Results: Median durations of cardiopulmonary bypass and cardioplegic arrest were
74 and 60 minutes, respectively. Compared with precardiopulmonary bypass, post-
cardiopulmonary bypass myocardial tissues revealed 480 up-regulated and 626
down-regulated genes with a threshold P value of .025 or less (signal-to-noise ratio:
3.46); skeletal muscle tissues showed 560 and 348 such genes, respectively (signal-
to-noise ratio: 3.04). Up-regulated genes in cardiac tissues included inflammatory
and transcription activators FOS; jun B proto-oncogene; nuclear receptor subfamily
4, group A, member 3; MYC; transcription factor-8; endothelial leukocyte adhesion
molecule-1; and cysteine-rich 61; apoptotic genes nuclear receptor subfamily 4,
group A, member 1 and cyclin-dependent kinase inhibitor 1A; and stress genes
dual-specificity phosphatase-1, dual-specificity phosphatase-5, and B-cell translo-
cation gene 2. Up-regulated skeletal muscle genes included interleukin 6; interleu-
kin 8; tumor necrosis factor receptor superfamily, member 11B; nuclear receptor
subfamily 4, group A, member 3; transcription factor-8; interleukin 13; jun B
proto-oncogene; interleukin 1B; glycoprotein Ib, platelet, alpha polypeptide; and
Ras-associated protein RAB27A. Down-regulated genes included haptoglobin and
numerous immunoglobulins in the heart, and factor H-related gene 2, protein
phosphatase 1, regulatory subunit 3A, and growth differentiation factor-8 in skeletal
muscle.
Conclusions: By establishing a profile of the gene-expression responses to cardio-
pulmonary bypass and cardioplegia, this study allows a better understanding of their
effects and provides a framework for the evaluation of new cardiac surgical
modalities directly at the genome level.
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Cardiopulmonary bypass (CPB) and car-dioplegic arrest are used in more than300,000 patients who undergo cardiac sur-gery in the United States every year. Al-though off-pump coronary surgery has re-cently gained in popularity, CPB and
cardioplegic arrest are still employed in more than 75% of
coronary artery bypass grafting (CABG) procedures and for
virtually every other type of adult cardiac operation. Al-
though these modalities are indispensable adjuncts, they are
also paradoxically responsible for a large part of the mor-
bidity associated with cardiac surgery. CPB is associated
with disturbances of virtually every organ system, mediated
by its elicitation of a whole-body inflammatory response.1-4
Cardioplegic arrest may result in coronary vasomotor dys-
function, ischemia-reperfusion injury, myocardial edema,
perioperative myocardial infarction, and low cardiac output
syndrome.5-7
Transcriptional profiling using high-density microarrays
provides unique data about disease mechanisms, drug re-
sponses, regulatory pathways, and gene function by com-
paring the level of mRNA transcribed in cells in a given
pathologic state versus a control. This allows for the eluci-
dation of complex pathophysiologic mechanisms directly at
the gene expression level.8 We examined the cardiac and
skeletal muscle gene expression profiles of patients under-
going cardiac surgery with CPB and cardioplegic arrest to
improve the understanding of these modalities and provide
a reference framework for the evaluation of prognostic gene
markers and new intraoperative strategies.
Methods
Tissue Samples
After the protocol was approved by the research ethics committee
of the Beth Israel Deaconess Medical Center and informed consent
was obtained from the patients, samples of right atrium and skel-
etal muscle were collected immediately before and after CPB in 16
patients undergoing primary elective CABG. Samples were har-
vested with cold sharp dissection and handled in a nontraumatic
fashion.
Right atrial samples consisted of nontraumatized tissue that
was not involved in a purse string suture. Pre-CPB tissues were
taken from the right atrial appendage before venous cannulation,
and post-CPB atrial samples were harvested after the construction
of a second purse string suture on the right atrial appendage and
decannulation. Skeletal muscle samples were taken from the left
intercostal muscle bed, lateral to the internal thoracic artery harvest
site. Atrial and skeletal muscle samples (10 10 2 mm) were
snap-frozen in liquid nitrogen and immediately stored at 80°C.
To minimize baseline phenotypic variation, 5 patients aged
between 55 and 75 years, who were normocholesterolemic, non-
smoking, nondiabetic, of the same ethnicity and gender, and who
had similar procedural characteristics, were selected from the 16
subjects whose tissues were harvested; 10 atrial (ie, 5 pre- and 5
post-CPB and cardioplegic arrest) and 10 skeletal muscle (ie, 5
pre- and 5 post-CPB) samples obtained from these patients were
therefore used for the microarrays analyses and the validation
studies (Table 1).
RNA Isolation
Total RNA was isolated with a Trizol-based method, following the
manufacturer’s protocol (Gibco BRL, Rockville, Md), on samples
of approximately 200 mg. Purification was achieved by passing the
RNA samples through an RNAeasy column (Qiagen, Valencia,
Calif). Residual DNA contamination was eliminated by DNase I
treatment (Invitrogen, San Diego, Calif). RNA concentrations
were determined by spectrophotometry; each sample yielded a
minimum of 5 g of total RNA at a minimum concentration of 0.5
g/L with an A260/A280 ratio ranging between 1.8 and 2.1.
Microarray Processing
cDNA was prepared according to protocols provided with the
Affymetrix U95 GeneChip system (Affymetrix, Santa Clara, Cal-
if).9 Five micrograms of total RNA were used in the first-strand
cDNA synthesis with T7-d(T)24 primer (GGCCAGTGAATTG-
TAATACGACTCACTATAGGGAGGCGG-[dT]24) and Super-
script II (Gibco-BRL, Gaithersburg, Md). The second-strand
cDNA synthesis was performed at 16°C by adding Escherichia
coli DNA ligase, DNA polymerase I, and RNase H to the reaction,
followed by T4 DNA polymerase to blunt the ends of newly
synthesized cDNA. The cDNA was purified through phenol/chlo-
roform and ethanol precipitation. By using a BioArray High Yield
RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale,
NY), the purified cDNA was incubated for 5 hours at 37°C in an
in vitro transcription reaction to produce cRNA-labeled with bi-
otin.
Microarray Hibridization
cRNA was fragmented by incubating in a buffer containing 200
mmol/L Tris-acetate, 500 mmol/L KOAc, and 150 mmol/L
TABLE 1. Patient characteristics
Atrial myocardial (N  5)
and skeletal muscle
(N  5) samples*
Age (yr)† 66 (55, 72)
Men/women, n 5/0
Hypertension, n 5
Current tobacco use, n 0
Cholesterol  200 mg/dL, n 0
Diabetes, n 0
Redo or combined cardiac procedure, n 0
Number of grafts performed† 3 (3, 4)
Duration of CPB (min)† 74 (67, 99)
Duration of cardioplegic arrest (min)† 60 (44, 83)
Minimum CPB temperature (°C)† 34 (33, 35)
Intraoperative blood transfusion, n 0
Postoperative length of stay (d)† 6 (4, 9)
CPB, Cardiopulmonary bypass.
*One tissue sample was collected from each site before and after CPB in
each patient.
†Data expressed as median (minimum, maximum).
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MgOAc for 35 minutes at 94°C. Fifteen micrograms of fragmented
cRNA were mixed with eukaryotic hybridization controls (con-
taining control cRNA and oligonucleotide B2) and hybridized with
a pre-equilibrated human U95Av2 Affymetrix chip for 16 hours at
45°C. The chips were washed in a fluidic station with low-strin-
gency buffer (6 standard saline phosphate with EDTA, 0.01%
Tween 20, and 0.005% antifoam) for 10 cycles and in high-
stringency buffer (100 mmol/L N-morpholino-ethanesulfonic acid,
0.1 mol/L NaCl, and 0.01% Tween 20) for 4 cycles and stained
with streptavidin phycoerythrin. This process was followed by
incubation with normal goat immunoglobulin G and biotinylated
mouse anti-streptavidin antibody, and restaining with streptavidin
phycoerythrin.
Statistical Analysis of Microarray Data
The chips were scanned in an HP G2500A ChipScanner (Af-
fymetrix) to detect hybridization signals. Image output files were
visually examined for major chip defects and hybridization arti-
facts, and raw data were processed with GeneChip Microarray
Analysis Suite 5.0 software (Affymetrix). The image from each
chip was scaled such that the absolute signal intensities were
adjusted to target intensity and reported as a non-negative numer-
ical quantity. Data were imported into SAS version 7 (SAS, Cary,
NC) for further analysis. Statistical techniques were separately
applied to each type of tissue and involved tests that were paired
for each patient.
Median post- to pre-CPB and cardioplegic arrest gene expres-
sion ratios were computed for each gene by using the relative
signal intensities of the probe cells. Two statistical methods were
combined to assess differential gene expression between the pre-
and post-CPB and cardioplegic arrest tissues.10 To ensure a min-
imal number of false positives, only the probe sets commonly
yielded by the 2 methods were included in the list of genes
differentially expressed in post- versus pre-CPB and cardioplegic
arrest samples.
Method 1 identified probe sets with significant intensity differ-
ences between pre- and post-CPB and cardioplegic arrest tissues.
For each tissue type, a Wilcoxon signed-rank test was applied to
the absolute signal intensities of each gene in the pre- versus
post-CPB and cardioplegic arrest data set. The use of a nonpara-
metric, paired Wilcoxon test was selected over that of a standard
t test to avoid a distributional assumption;11,12 the threshold was
set at a P value of .0253 or less, which corresponds to the lowest
possible P value in the particular experimental setting of the study
(observed when 5 of 5 patients show a similar pattern of differ-
ential expression). By using this P value, the number of genes that
could have reached significance by chance alone was determined
and compared with the number of observed significant genes, and
a signal-to-noise ratio was computed.
Method 2 determined the differentiability of a probe set by its
signal intensity fold change. Nonparametric determination of
genes with significantly different fold changes between the pre-
and post-CPB and cardioplegic arrest states was performed by
computing and ordering by increasing size the median relative
signal intensities of each probe set. A particular gene was consid-
ered to be up-regulated after CPB and cardioplegic arrest in a
given tissue type if a median fold change of 4 (4:1) or more was
observed in post- versus pre-CPB and cardioplegic arrest samples.
Conversely, a gene was considered down-regulated if the median
fold change of post- versus pre-CPB and cardioplegic arrest sam-
ples was 0.25 (1:4) or less. Only genes identified by both methods
were considered to be differentially expressed and were reported.
Microarray Validation
Northern analysis. cDNA probes of human DUSP1 and
CYR61 (2 significantly altered genes), and GADP and -actin (2
genes that were not altered) were labeled with 32P-dCTP (New
England Nuclear, Boston, Mass) using a random-priming labeling
kit (Boehringer, Indianapolis, Ind) and purified from unincorpo-
rated nucleotides using G-50 Quick Spin Columns (Boehringer).
The blots were hybridized overnight at 48°C using an Ambion
Northern Max kit (Ambion, Austin, Tex). After hybridization, the
blots were washed twice in 2 standard saline citrate with 0.1%
sodium dodecyl sulfate (SDS) for 15 minutes each at room tem-
perature and then washed twice in 0.1 standard saline citrate with
0.1% SDS for 15 minutes each at 60°C. Autoradiography was
performed for 20 hours at 80°C. Blots were analyzed after
digitization and quantification of x-ray films with the Image-Quant
software (Molecular Dynamic, Sunnyvale, Calif), quantified as a
ratio of the gene mRNA to loading band density, and presented as
a median (minimum, maximum) ratio of post- to pre-CPB and
cardioplegic arrest mRNA expression.
Real-time polymerase chain reaction. Reverse transcription
was performed on 2 g of total RNA isolated from atrial and
skeletal muscle tissues, using an oligo dT primer (Invitrogen) for
90 minutes at 37°C. DUSP1 primers were forward-TGGAG-
GAAGGGTGTTTGTCC, reverse-CAAGGCAGATGGTG-
GCTGA, and TaqMan-FAM-CTGCCAGGCAGGCATTTCCCG-
TAMRA (Applied Biosystems, Foster City, Calif). CYR61
primers were forward-ATCAAGGACCCCATGGAGG, reverse-
AGGCATCGAATCCCAGCTC, and TaqMan-FAM-CCAG-
GACGGCCTCCTTGGCAA-TAMRA (Applied Biosystems).
Amplification conditions were as follows: stage 1, 1 cycle for 2
minutes at 50°C; stage 2, 1 cycle for 10 minutes at 95°C; stage 3,
40 cycles for 15 seconds at 95°C and 1 minute at 60°C. Real-time
detection was accomplished using SYBR Green I dye and fluo-
rescence quantified with a GeneAmp Sequence Detection System
(Applied Biosystems). All experiments were performed in dupli-
cate, and post- to pre-CPB and cardioplegic arrest ratios of poly-
merase chain reaction (PCR) products are presented as median
(minimum, maximum) ratios.
In situ hybridization. Probes for human DUSP1 and CYR61
were generated from PCR fragments containing T3 (forward) and
T7 (reverse) promoter sequences incorporated in the amplicon.
Frozen sections of 10 m were cut in a cryostat and captured onto
microscope slides. Sections were fixed and acetylated, and hybrid-
ized at 68°C to the probe for 3 nights. Hybridized probes were
visualized using alkaline phosphatase-conjugated anti-DIG Fab
fragments and 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue
tetrazolium substrate (Kierkegard and Perry, Gaithersburg, Md).
Sections were rinsed several times in 100 mmol/L Tris, 150
mmol/L NaCl, and 20 mmol/L EDTA pH 9.5, and coverslipped
with glycerol gelatin. Control sections were incubated in an iden-
tical concentration of the sense probe transcript. In situ hybridiza-
tion autoradiographs were evaluated qualitatively in random high-
power fields.
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TABLE 2. Genes exhibiting a fourfold or greater increase in expression in post- versus pre-cardiopulmonary bypass and
cardioplegic areas atrial samples
Gene name Symbol
GenBank
accession
number
Expression
ratio
(post:pre)* Function
Proto-oncogene C-FOS FOS K00650 20:1 Pro-apoptotic transcription factor, acting with JUN
Nuclear receptor subfamily 4,
group A, member 1
NR4A1 L13740 19:1 Steroid receptor; regulates apoptosis
Proto-oncogene JUN-B JUNB M29039 17:1 Similar to JUN; pro-apoptotic transcription factor acting with
FOS
Nuclear receptor subfamily 4,
group A, member 2
NR4A2 X75918 15:1 Coactivator of transcription; stimulated by PGE2, IL1B, and
TNF
Dual-specificity phosphatase 1 DUSP1 X68277 12:1 Regulator of the cellular response to stress
Zinc finger transcriptional
regulator
ZFP36 M92843 10:1 Component of a negative feedback loop that interferes with
TNF production
Transcription factor 8 TCF8 D15050 10:1 Negative regulator of T-lymphocyte IL2 gene expression
Nuclear receptor subfamily 4,
group A, member 3
NR4A3 D78579 7:1 Transcription factor
Oncogene FOS-B FOSB L49169 7:1 Transcription factor; its truncated form may act to limit the
transcriptional effects of FOS and JUN
Solute carrier family 2, member
3
SLC2A3 M20681 6:1 Facilitation of glucose transport in tissues with a high glucose
demand
Cellular oncogene C-FOS FOS V01512 6:1 Pro-apoptotic transcription factor, acting with JUN
Dual-specificity phosphatase 5 DUSP5 U15932 6:1 Protein-tyrosine phosphatase induced by serum stimulation
and heat shock
MADS box transcription
enhancer factor 2
MEF2C S57212 6:1 Transcription factor
Cyclin dependent kinase-like 1 CDKL1 X6358 6:1 Cell cycle regulator
Small inducible cytokine A2 SCYA2 M26683 6:1 Chemotactic factor for monocytes; regulated by NF-kappa-B
Oncogene MYC MYC V00568 5:1 Transcription factor
B-cell translocation gene 2 BTG2 U72649 5:1 Cell cycle regulator in response to DNA damage
T-cell cytokine receptor TCCR AF053004 5:1 Class I cytokine receptor; involved in the early immune
response
Plasminogen activator receptor,
urokinase-type
PLAUR U09937 5:1 Involved in neutrophil recruitment
Activating transcription factor 3 ATF3 L19871 5:1 Transcription factor
Early growth response 2 EGR2 J04076 5:1 Transcription factor
Argininemia gene ARG1 M14502 5:1 Hydrolyzes arginine to urea and omithine in the urea cycle
Sortilin 1 SORT1 X98248 5:1 Involved in sorting proteins to endosomal vesicles and golgi
E-selectin SELE M24736 4:1 Adhesion of leukocytes to cytokine-stimulated endothelial cells
Kappa casein CSN10 M73628 4:1 Unknown
Cytokine GRO2 GRO2 M36820 4:1 Chemotactic agent for polymorphonuclear leukocytes;
regulated by IL1B, TNF, and LPS
Cysteine-rich angiogenic inducer
61
CYR61 Y11307 4:1 Immediate-early transcription factor; promotes adhesion of
endothelial cells, chemotaxis, and angiogenesis
S100 calcium-binding protein A4 S100A4 M80563 4:1 Elevated serum levels have been correlated with cerebral
damage after cardiopulmonary bypass and circulatory arrest
Histone H1F3 H1F3 M60747 4:1 Basic nuclear proteins responsible for the nucleosome
structure
Fibronectin 1 FN1 AJ001487 4:1 Stimulates endocytosis and clearance of C1q-coated material
such as immune complexes, cellular debris, or particulate
material from the circulation
mRNA export protein 1 RAE1 U85943 4:1 Nucleocytoplasmic transport of mRNAs
Cyclin-dependent kinase
inhibitor 1A
CDKN1A U03106 4:1 Associated with apoptosis of human endothelial cells
nF, Nuclear factor; IL, interleukin; TNF, tumor necrosis factor; LPS, Lipopolysaccharide.
*Median expression ratio of post-CPB versus pre-CPB samples.
Cardiopulmonary Support and Physiology Ruel et al
1524 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
CSP
Immunoblotting. Total lysate from atrial and skeletal muscle
tissues was obtained by 30-second homogenization on ice in lysis
buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, and a protease inhibitor, and centrifuged at 12,000g for 10
minutes at 4°C to separate soluble from insoluble proteins. The
supernatant protein concentration was measured spectrophoto-
metrically at 595 nm wavelength using a BCA protein assay kit
(Pierce, Rockford, Ill). Total protein was fractionated on 10%
SDS-polyacrylamide gel electrophoresis and transferred to a poly-
vinylidene difluoride membrane (Millipore, Bedford, Mass) using
a semi-dry transfer apparatus. Membranes were stained with Pon-
ceau S and incubated with 5% nonfat dry milk in 50 mmol/L
Tris-HCl, pH 8.0, 100 mmol/L NaCl, and 0.1% Tween 20 (TBST)
buffer for 1 hour at room temperature. Membranes were incubated
with antibodies (in 2.5% nonfat dry milk in TBST) (anti-DUSP1
1:1000 [v/v] dilution, rabbit polyclonal 1:1000 [v/v], or anti-
CYR61 1/1000 [v/v] dilution), and rabbit polyclonal (Santa Cruz
Biotechnology, Santa Cruz, Calif) for 2 hours. After washing with
TABLE 3. Genes exhibiting a fourfold or greater decrease in expression in post- versus pre-cardiopulmonary bypass and
cardioplegic arrest atrial samples
Gene name Symbol
GenBank
accession
number
Expression
ratio
(post:pre)* Function
Immunoglobulin gamma 3 IGHG3 Y14737 1:47 Heavy chain immunoglobulin
Annexin A8 ANXA8 X16662 1:23 Vascular anticoagulant beta; function in heart unknown
Immunoglobulin kappa constant
region
IGKC M63438 1:18 Light chain immunoglobulin
Immunoglobulin lambda constant
region 1
IGLC1 M18645 1:16 Light chain immunoglobulin
Haptoglobin HP X00442 1:16 Binds free hemoglobin and protects against bacterial
growth
Immunoglobulin mu IGHM X67301 1:16 Heavy chain immunoglobulin
Immunoglobulin lambda-like light
chain 3 (incomplete sequence)
— A1932613 1:9 Light chain immunoglobulin
Keratin 7 KRT7 AJ238246 1:7 Unknown
Protein tyrosine phosphatase,
non-receptor, type 2
PTPN2 M25393 1:7 Regulator of cell growth and differentiation
Centrin 1 CETN1 U03270 1:6 Involved in centrosome segregation and microtubule
severing
Immunoglobulin alpha constant
heavy chain 2
IGHA2 S71043 1:6 Heavy chain immunoglobulin
Properdin factor B BF L15702 1:6 Serine protease; C3 proaccelerator
Hexosaminidase B HEXB M23294 1:6 Ganglioside breakdown
Cyclin E2 CCNE2 AF091433 1:5 DNA synthesis initiator
Tumor necrosis factor receptor
superfamily, member 7
TNFRSF7 M63928 1:5 Cell growth, differentiation, and apoptosis
Immunoglobulin lambda constant
region
IGLC X57809 1:5 Light chain immunoglobulin
Kallikrein 11 KLK11 AB012917 1:5 Serine protease
RAS inhibitor RIN1 L36463 1:4 Inhibitor of RAS-mediated cell growth and
differentiation
Carcinoembryonic antigen-
related cell adhesion molecule
CEACAM1 X16354 1:4 Member of the immunoglobulin superfamily
Haptoglobin-related protein HPR X89214 1:4 Similar to haptoglobulin
Immunoglobulin J chain IGJ AI660656 1:4 Synthesized in B lymphocytes; links immunoglobulin
monomers
RAL guanine nucleotide
dissociation stimulator
RALGDS AB002349 1:4 RAS-related GTPases; cell signaling
Phosphoenolpyruvate
carboxykinase 2
(mitochondrial)
PCK2 X92720 1:4 Gluconeogenesis
Mast cell carboxypeptidase A MC-CPA M73720 1:4 Unknown
DMX-like 1 protein DMXL1 AJ005821 1:4 Protein–protein interactions and regulation
Neuronal nicotinic acetylcholine
receptor alpha-7 subunit
CHRNA7 X70297 1:4 Alpha 7 subunit of the neuronal nicotinic acetylcholine
receptor
*Median expression ratio of post-CPB versus pre-CPB samples.
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TABLE 4. Genes exhibiting a fourfold or greater increase in expression in post- versus pre-cardiopulmonary bypass
skeletal muscle samples
Gene name Symbol
GenBank
accession
number
Expression
ratio
(post:pre)* Function
Interleukin 6 IL6 X04430 20:1 Mediates leukocytosis, thrombosis, and lymphocyte
activation
Interleukin 8 IL8 M28130 18:1 Mediates neutrophils chemotaxis and migration
Tumor necrosis factor receptor
superfamily, member 11B
TNFRSF11B AB008822 13:1 Secreted by T cells; mediates inflammation
Nuclear receptor subfamily 4, group
A, member 3
NR4A3 D78579 9:1 Transcription factor
Nuclear receptor subfamily 4, group
A, member 1
NR4A1 L13740 8:1 Steroid receptor; regulates apoptosis
Transcription factor 8 TCF8 D15050 6:1 Negative regulator of T-lymphocyte IL2 gene expression
Early growth response 3 EGR3 X63741 6:1 Immediate-early transcription activator; induced by
stress or injury
Cholesterol 25-hydroxylase CH25H AF059214 6:1 Regulation of cholesterol and lipid metabolism
T-cell receptor interacting molecule TRIM AJ224878 6:1 Associates with the TCR-CD3 complex in T lymphocytes
after T-cell activation
Endothelin 1 EDN1 J05008 6:1 Potent vasoconstrictor produced by endothelial cells
Transforming growth factor-beta
receptor, type 1
TGFBR1 AF054598 6:1 Proliferation and differentiation of fibroblasts
Interleukin 13 IL13 U31120 6:1 Expressed in activated human T lymphocytes; synergizes
with IL2 in regulating inflammatory and immune
responses
Ephrin B2 EFNB2 U81262 6:1 Angiogenesis and vascular remodeling
Activating transcription factor 2 ATF2 L05515 5:1 Transcription factor
T-cell tyrosine kinase EMT EMT L10717 5:1 TCR-mediated CD4 stimulation
Oncogene JUN-B JUNB X51345 5:1 Pro-apoptotic transcription factor acting with FOS
TAF13 RNA polymerase II TAF13 X84003 5:1 Mediates the function of gene promoters and
transcriptional activators
ATPase, class 1, type 8A, member 2 ATP8A2 AI017981 5:1 Transport of ions across cell membranes
Solute carrier family 2, member 3 SLC2A3 M20681 5:1 Facilitated glucose transporter in tissues that exhibit a
high glucose demand
Platelet glycoprotein 1B, alpha
polypeptide
GP1BA J02940 5:1 Platelet adhesion
Signal-induced proliferation-
associated gene 1
SIPA1 AB005666 5:1 Involved with IL2 in mitogen-induced cell cycle
progression
CD44 surface antigen CD44 L05424 5:1 Matrix adhesion and migration of lymphocytes from the
bloodstream to lymphatic tissues
Inhibitor of kappa light chain gene
enhancer in B cells, epsilon
IKBE U91616 5:1 Inhibits NF-kappa-B transcription
TEC protein tyrosine kinase TEC D29767 4:1 Expressed in myeloid, B-, and T-cell lineages
Dual-specificity phosphatase 2 DUSP2 L11329 4:1 A MAP kinase phosphatase
Runt-related transcription factor 1 RUNX1 X90976 4:1 Transcription factor
TAF1 RNA polymerase II TAF1 X07024 4:1 Mediates the function of gene promoters and
transcriptional activators
Protease inhibitor 9 PI9 U71364 4:1 Serine protease inhibitor
Protein-tyrosine phosphatase,
receptor-type, J
PTPRJ U10886 4:1 Modulation of biologic cascades
Activated leukocyte cell adhesion
molecule
ALCAM Y10183 4:1 T-cell receptor; involved in cell adhesion interactions
RAS-associated protein RAB27A RAB27A U57094 4:1 Platelet vesicular transport
Interleukin 1-beta IL1B M15330 4:1 Cytokine involved in inflammation, cell-cell signaling,
signal transduction, and the antimicrobial response
*Median expression ratio of post-CPB versus pre-CPB samples.
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TBST, the membranes were incubated for 1 hour in 2.5% nonfat
dry milk in TBST diluted with anti-rabbit immunoglobulin G
(Jackson Immunolabs, West Grove, Pa), both at 1:3000 (v/v)
dilution conjugated to horseradish peroxidase. Peroxidase activity
was visualized using enhanced chemiluminescence and exposed to
x-ray films (Amersham, Arlington Heights, Ill). Post-CPB to pre-
CPB and cardioplegic arrest ratios of protein density are presented
as median (minimum, maximum) ratios.
Reporting and Functional Classification
Genes identified to be significant by microarray analysis with both
statistical methods were the object of a literature search and
reported, along with their GenBank accession number, according
to the current nomenclature of Online Mendelian Inheritance in
Man.13 Functional inferences outlined in the right column of
Tables 2 to 5 are based on the authors’ interpretation of literature
referenced in Online Mendelian Inheritance in Man pertaining to
each gene.
Results
Patient Characteristics
Table 1 displays the clinical characteristics of the patients
whose tissues were used for the microarray and validation
studies. All subjects were Caucasian men aged between 55
and 72 years old, without significant comorbidity, who
electively underwent 3 or 4 CABGs with mildly hypother-
mic CPB and antegrade intermittent (every 20 minutes)
hyperkalemic cold blood cardioplegia. Antifibrinolytic
drugs were not administered.
Microarray Signal-to-Noise Characteristics
Of 12,625 genes examined, 1,106 and 974 genes were
identified by method 1 to have a P value of .0253 or less for
their differential expression in post- versus pre-CPB and
cardioplegic arrest cardiac and skeletal muscle tissues, re-
spectively (Figure 1). The projected number of genes that
could have reached significance because of chance alone
was 320 for each tissue type, corresponding to a signal-to-
noise ratio of 3.46 in cardiac and 3.04 in skeletal muscle
microarrays.
Identification of Significantly Altered Genes
Genes whose expression was found to be significantly al-
tered by using both methods are reported in Tables 2 to 5.
Of these, there were 32 up-regulated and 26 down-regulated
genes in the heart (Tables 2 and 3), and 32 and 7 such genes
in the skeletal muscle (Tables 4 and 5). Most up-regulated
atrial genes were transcription factors, and most down-
regulated atrial genes were immunoglobulins. In skeletal
muscle, transcription factors also represented a large pro-
portion of the up-regulated genes, but no specific functional
pattern was observed in the down-regulated genes.
Validation
DUSP1. The microarray results for DUSP1 revealed
increased expression (median 12-fold; 3.2, 27.1; P  .025)
in the atrium, but no significant change in the skeletal
muscle after CPB and cardioplegic arrest (median 1.6-fold;
0.3, 6.5; P  .68). Validation studies revealed the median
mRNA expression of DUSP1 in post- versus pre-CPB atrial
samples to be increased 3-fold (1.7, 7.1; P  .025) and
6.4-fold (1.5, 16.8; P  .05) by Northern blotting and
real-time PCR, respectively, with a change in protein level
of 4.6-fold (1.3, 5.7; P  .05) by immunoblotting (Figure
2). In skeletal muscle, DUSP1 was not significantly up-
regulated, with a median differential mRNA expression of
1.6-fold (1.2, 4.6; P .08) and 8.2-fold (2.5, 23.3; P .08)
by Northern blotting and PCR, respectively, and a protein
level change of 2.1-fold (1.1, 3.0; P  .68) by immunoblot-
ting. In situ hybridization revealed a striking increase in
DUSP1 expression in atrial tissues, particularly localized to
TABLE 5. Genes exhibiting a fourfold or greater decrease in expression in post- versus pre-cardiopulmonary bypass
skeletal-muscle samples
Gene name Symbol
GenBank
accession
number
Expression
ratio (post:
pre)* Function
Factor H-related gene 2 FHR2 X64877 1:7 Structurally and immunologically related to complement
factor H
T-box 1 TBX1 AF012130 1:5 Transcription factor
Protein phosphatase 1, regulatory
subunit 3A
PPP1R3A AF024578 1:5 Centrally involved in carbohydrate and lipid metabolism;
down-regulation or mutation can cause severe
insulin resistance
RAS-related protein 2A RAP2A X12534 1:5 Unknown
Growth/differentiation factor 8 GDF8 AF104922 1:4 Maintenance of skeletal muscle homeostasis
Chorionic gonadotropin, beta chain CGB J00117 1:4 Function in skeletal muscle unclear
Cleavage and polyadenylation
specificity factor 6
CPSF6 X67337 1:4 Processing of primary mRNA transcripts
*Median expression ratio of post-CPB versus pre-CPB samples.
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the endothelium and myocytes (Figure 3). No increase in
expression was detected in skeletal muscle samples.
CYR61. The microarray results for CYR61 revealed in-
creased expression in the atrium (median 4-fold; 1.5, 12.1;
P  .025), but no significant change in the skeletal muscle
after CPB and cardioplegic arrest (median 4-fold; 0.8, 8; P
 .68). In concordance with these results, the median ex-
pression of CYR61 in post- versus pre-CPB atrial samples
was 2.5-fold (1.8, 5.3; P  .025) and 6.2-fold (1.4, 15.4; P
.025) by Northern blotting and real-time PCR, respec-
tively (Figure 2). The amount of protein was also increased
2.7-fold (1.5, 3.2; P  .05) in atrial tissues. In the skeletal
muscle, CYR61 was not significantly up-regulated, with a
median differential expression of 1-fold (1, 2.3; P .16) by
Northern blotting, 4.9-fold (1, 15.9; P  .08) by PCR, and
2.7-fold by immunoblotting (0.9, 3.2; P  .68).
GAPD and -Actin. Microarray results revealed the dif-
ferential expression of these genes not to be significantly
altered after CPB and cardioplegic arrest in both atrial and
skeletal muscle tissues. On Northern blotting, the median
differential expression of post-CPB and cardioplegic arrest
to pre-CPB samples was 1.2 and 1.1 for GAPD, and 1.0 and
1.1 for -actin in atrial and skeletal muscle samples, respec-
tively (P  not significant).
Discussion
In this study, the gene expression profile of atrial and
skeletal muscle from selected, phenotypically similar pa-
tients undergoing cardiac surgery with CPB and cardiople-
gic arrest was determined. The microarray-based method
was feasible and validated with conventional quantification
techniques. A large number of genes showing altered tran-
scription with a subthreshold P value were identified, well
in excess of the number projected to have reached this P
value threshold by multiple testing alone. We determined
that CPB and cardioplegic arrest do not cause an indiscrim-
inate change in gene expression, but rather induce a distinct
pattern of changes in specific pathways such as up-regula-
tion of inflammation/transcription activators, apoptotic
genes, and stress genes, as well as down-regulation of
immunoglobulin genes. These results allow a better under-
standing of the pathophysiology of CPB and cardioplegic
arrest on cardiac and peripheral tissues and introduce a new
method for evaluating modalities aimed at minimizing the
adverse effects of CPB, cardioplegia, and cardiac surgery by
directly measuring the overall gene expression profile and
response of target groups of genes.
Several of the genes found to be differentially expressed
in this study have been implicated in the pathophysiology of
CPB and cardioplegia in humans. FOS and JUN were found
to be up-regulated in subendocardial myocytes and endo-
thelial cells of right atrial samples after cold crystalloid
cardioplegia.14,15 Nuclear factor-kappa B activation has
Figure 2. Northern and Western blot analyses of mRNA expres-
sion and protein level of DUSP1 and CYR61 in atrial (heart) and
skeletal muscle (Sk.M.) tissues, pre- and post-CPB and cardio-
plegia. mRNA expression and protein levels of DUSP1 and CYR61
were significantly increased in post- versus pre-CPB atrial sam-
ples, but not in the skeletal muscle.
Figure 1. Genes that were differentially expressed with a P value of .0253 or less after cardiopulmonary bypass
(CPB) and antegrade cold blood cardioplegia in cardiac (left) and skeletal muscle tissues (right) (of 12,625 genes
examined). These genes and the number expected to result from repeat testing alone were identified by method
1 described in the text.
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been proposed as an inducer of transcription in right atrial
tissue exposed to ischemia-reperfusion,16 and endothelin 1
receptor blockade has been associated with minimization of
left ventricular dysfunction after CPB and cardioplegic ar-
rest in swine.17 A number of neutrophil adhesion molecules
such as CD11 and CD44 have been differentially ex-
pressed,18,19 and serum levels of IL6, IL8, TNF, IL1B,
SCYA2, SELE, and IL13, and CD44 levels have been
shown to be increased after CPB.20-26 Elevated serum levels
of S100 have been correlated with cerebral damage after
CPB and circulatory arrest.27
This study also identifies multiple genes that had not
been implicated in the pathophysiology of CPB and car-
dioplegic arrest, such as DUSP1, TCF8, CYR61, SLC2A3,
MYC, TCCR, BTG2, TRIM, ALCAM, EFNB2, and many
others (Tables 2-5). Although the clinical significance of
these new findings is still unknown, further research may
characterize the expression of these genes, quantify poly-
morphisms, and examine their correlation with surgical
outcome.
Limitations
Microarray techniques, despite their immense potential to
improve disease understanding, have inherent shortcomings
related to the selection of tissues, lack of standardized
methods for the statistical analysis of data, presentation of
vast amounts of results, and generalizability of the find-
ings.28 Microarray technology also does not allow for the
determination of absolute expression patterns and provides
a measure of transcribed mRNA rather than a functional
gene product. We have attempted to limit these shortcom-
ings by selecting phenotypically and procedurally similar
subjects, combining nonparametric statistical methods to
minimize false positives, validating the expression patterns,
protein levels, and origin of select genes with conventional
molecular techniques, and suggesting a potential functional
role for genes whose expression was most strikingly altered.
For ethical reasons, we used human atrial biopsies rather
than ventricular biopsies to examine the cardiac gene ex-
pression changes that result from CPB and cardioplegic
arrest. Atrial sampling involves little or no intrinsic risk of
morbidity, provides full-thickness samples, and is clinically
reproducible. CPB and antegrade cold blood cardioplegia
distribute to the right atrium.29 Although atrial myocardium
differs from ventricular myocardium with respect to the
relative percentage of myocytic, endothelial, connective,
and neural elements, these cell types are present in each
tissue type and may demonstrate ultrastructural changes in
disease.30,31
Figure 3. Representative in situ hybridization images of DUSP1, pre- and post-CPB in atrial tissues. A post-CPB and
cardioplegic arrest increase in DUSP1 expression was localized to the endothelium (arrowheads) and myocytes
(small arrows).
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Conclusion
We believe that this study allows a better understanding of
the cardiac and systemic effects of CPB and cardioplegic
arrest. We anticipate that these data will serve as a starting
point for functional studies and provide a framework for the
use of gene expression approaches to better understand and
minimize the morbid effects of cardiac surgery on cardiac
and peripheral tissues.
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